AstraZeneca sets out $15 billion China investment during Starmer visit

Core Viewpoint - AstraZeneca plans to invest $15 billion in China by 2030 to enhance its medicines manufacturing and research and development capabilities [1] Company Investment - The investment is aimed at expanding AstraZeneca's operations in China, focusing on both manufacturing and R&D [1] Timeline - The investment will be made over the course of the next seven years, concluding in 2030 [1]